Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)

被引：33

作者：

Hofbauer, L. C. ^{[1
]}

机构：

[1] Univ Marburg, Zentrum Innere Med, Div Gastroenterol & Endocrinol, D-35033 Marburg, Germany

来源：

ANNALES D ENDOCRINOLOGIE | 2006年 / 67卷 / 02期

关键词：

D O I：

10.1016/S0003-4266(06)72569-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：139 / 141

页数：3

共 24 条

[1] The effect of a single dose of osteoprotegerin in postmenopausal women [J].

Bekker, PJ ;

Holloway, D ;

Nakanishi, A ;

Arrighi, M ;

Leese, PT ;

Dunstan, CR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360

[2] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[3] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[4] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].

Croucher, PI ;

Shipman, CM ;

Lippitt, J ;

Perry, M ;

Asosingh, K ;

Hijzen, A ;

Brabbs, AC ;

van Beek, EJR ;

Holen, I ;

Skerry, TM ;

Dunstan, CR ;

Russell, GR ;

Van Camp, B ;

Vanderkerken, K .

BLOOD, 2001, 98 (13) :3534-3540

[5] RANK is essential for osteoclast and lymph node development [J].

Dougall, WC ;

Glaccum, M ;

Charrier, K ;

Rohrbach, K ;

Brasel, K ;

De Smedt, T ;

Daro, E ;

Smith, J ;

Tometsko, ME ;

Maliszewski, CR ;

Armstrong, A ;

Shen, V ;

Bain, S ;

Cosman, D ;

Anderson, D ;

Morrissey, PJ ;

Peschon, JJ ;

Schuh, J .

GENES & DEVELOPMENT, 1999, 13 (18) :2412-2424

[6] Role of RANK ligand in mediating increased bone resorption in early postmenopausal women [J].

Eghbali-Fatourechi, G ;

Khosla, S ;

Sanyal, A ;

Boyle, WJ ;

Lacey, DL ;

Riggs, BL .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) :1221-1230

[7] Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment [J].

Giuliani, N ;

Bataille, R ;

Mancini, C ;

Lazzaretti, M ;

Barillé, S .

BLOOD, 2001, 98 (13) :3527-3533

[8] Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis [J].

Hofbauer, LC ;

Gori, F ;

Riggs, BL ;

Lacey, DL ;

Dunstan, CR ;

Spelsberg, TC ;

Khosla, S .

ENDOCRINOLOGY, 1999, 140 (10) :4382-4389

[9] Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases [J].

Hofbauer, LC ;

Schoppet, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :490-495

[10] Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord [J].

Honore, P ;

Luger, NM ;

Sabino, MAC ;

Schwei, MJ ;

Rogers, SD ;

Mach, DB ;

O'Keefe, PF ;

Ramnaraine, ML ;

Clohisy, DR ;

Mantyh, PW .

NATURE MEDICINE, 2000, 6 (05) :521-528

← 1 2 3 →